The Medicines Company has enrolled the first patient in a Phase III trial comparing the anticoagulant Angiomax (bivalirudin) to unfractionated heparin (UFH) in patients undergoing peripheral endovascular intervention (PEI). The Endomax Trial is the first randomized, double-blind, clinical trial to study pharmacology in patients undergoing PEI. PEI is performed in approximately 500,000 patients in the U.S. each year. Angiomax is currently approved for use in patients undergoing angioplasty, also...